Herantis Pharma
2.24 EUR
+5.92 %
4,574 following
HRTIS
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Investor consensus
+5.92 %
+27.28 %
+6.43 %
+9.56 %
+0.22 %
+64.34 %
+17.63 %
-24.92 %
-77.81 %
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read moreMarket cap
59.24M EUR
Turnover
104.17K EUR
P/E (adj.) (26e)
-17.11
EV/EBIT (adj.) (26e)
-15.67
P/B (26e)
7.82
EV/S (26e)
6,815.15
Dividend yield-% (26e)
-
Coverage
Analyst
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20/8
2026
Interim report Q2'26
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Webcast: Update on Phase 2 preparation
Herantis partners with Indivi in HER-096 Phase II trial
Join Inderes community
Research, tools and community to support better investment decisions.
Inderes account
Follow companies and get notifications on the ones you track
Analysts' recommendations and comments
Stock comparison tool and other popular tools
